Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells 70,000 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) EVP Craig E. Hunsaker sold 70,000 shares of Alphatec stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $7.16, for a total transaction of $501,200.00. Following the completion of the transaction, the executive vice president now owns 1,362,229 shares of the company’s stock, valued at approximately $9,753,559.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ:ATEC traded down $0.15 during trading hours on Friday, hitting $7.40. The company’s stock had a trading volume of 423,539 shares, compared to its average volume of 704,988. The stock has a market capitalization of $753.02 million, a P/E ratio of -4.48 and a beta of 1.59. The stock has a fifty day moving average of $10.24 and a 200-day moving average of $10.76. The company has a current ratio of 2.62, a quick ratio of 1.76 and a debt-to-equity ratio of 7.78. Alphatec Holdings, Inc. has a 52-week low of $6.92 and a 52-week high of $16.47.

Alphatec (NASDAQ:ATECGet Rating) last posted its earnings results on Thursday, May 5th. The medical technology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.14). The business had revenue of $70.93 million during the quarter, compared to analysts’ expectations of $67.72 million. Alphatec had a negative net margin of 60.83% and a negative return on equity of 147.10%. On average, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.31 earnings per share for the current year.

Several brokerages have commented on ATEC. HC Wainwright raised their price target on shares of Alphatec from $19.00 to $20.00 in a research report on Friday, May 6th. StockNews.com initiated coverage on Alphatec in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Piper Sandler cut their price objective on Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 2nd. Zacks Investment Research lowered Alphatec from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, Needham & Company LLC cut their price objective on Alphatec from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, May 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Alphatec has an average rating of “Hold” and an average price target of $18.71.

Large investors have recently bought and sold shares of the stock. LPL Financial LLC increased its holdings in Alphatec by 17.7% in the third quarter. LPL Financial LLC now owns 127,629 shares of the medical technology company’s stock valued at $1,556,000 after buying an additional 19,154 shares during the last quarter. Advisor Group Holdings Inc. increased its holdings in Alphatec by 65.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 35,787 shares of the medical technology company’s stock valued at $408,000 after buying an additional 14,153 shares during the last quarter. Deerfield Management Company L.P. Series C grew its holdings in shares of Alphatec by 5.7% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,594,829 shares of the medical technology company’s stock worth $43,821,000 after purchasing an additional 192,445 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Alphatec by 4.6% during the third quarter. Voya Investment Management LLC now owns 27,702 shares of the medical technology company’s stock worth $338,000 after purchasing an additional 1,219 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Alphatec by 945.3% during the third quarter. Point72 Asset Management L.P. now owns 3,062,091 shares of the medical technology company’s stock worth $37,327,000 after purchasing an additional 2,769,149 shares during the last quarter. 53.52% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Further Reading

Insider Buying and Selling by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.